IPAB upholds Natco’s Compulsory License on Nexavar
Natco, Hyderabad-based generic manufacture, had filed for a Compulsory License on Bayer’s Cancer Drug Nexavar in July 2011 as the reasonable requirement of public was...
Read MoreBayer’s Appeal Rejected
Bayer’s petition for stay with respect to the compulsory licensing order of the patent office relating to Nexavar, a cancer drug, has been rejected. The IPAB refused to...
Read MoreCOMPULSORY LICENCE FOR PHARMACEUTICAL PRODUCTS
The Australian Government has proposed a new Intellectual Property Laws Amendment Bill, 2012 in order to comply with the additional compulsory licensing provision under...
Read MoreIndia’s compulsory license grant not justified: USPTO
In light of February’s grant of India’s first Compulsory license, the US House of Representatives along with the US Patent and Trademark Office (USPTO) has expressed...
Read MoreCopyright Board Has No Powers to Grant Interim Relief- Supreme Court
Super Cassettes Industries v. Music Broadcasting Pvt. Ltd. Putting an end to a much debated copyright issue of recent time, the Apex Court, on 3rd May, held that the...
Read MoreCipla Slashes Cancer Drug Prices
As the ongoing battle between Bayer and Natco continues, Cipla slashes the prices of its liver, kidney and brain cancer drugs by upto 76%. In March 2012, by a landmark...
Read More